Merck KGaA Keen To Remain Key Player In MS Now And In Future
The German company is predicting sales in mid-triple-digits in 2019 for Mavenclad, its multiple sclerosis drug which has just been launched in the US, and has highlighted more promising MS data for its BTK inhibitor evobrutinib.
You may also be interested in...
The German company is exposed to events in China across its three divisions - healthcare, life sciences and performance materials - but says that COVID-19 should only affect 2020 sales by 1%, unless a global recession happens.
Novartis looks to differentiate ofatumumab from Roche's entrenched MS blockbuster Ocrevus, stressing that patients can inject the therapy at home.
Merck KGaA said its second-quarter performance was boosted by its Life Science lab unit and milestone payments from drug development partners and promised analysts a pipeline update next month.